Abstract 5189
Background
Small cell lung cancer (SCLC) is a highly lethal disease. Recently, immunotherapy has demonstrated a benefit for a subgroup of patients beyond the second-line and in the first-line setting combined with chemotherapy. However, the majority of patients will not benefit and predictive biomarkers are urgently needed. High baseline neutrophil count (NC) and neutrophil-to-lymphocyte ratio (NLR) are unfavorable prognostic factors in SCLC and might also predict for lack of response to immunotherapy. There is data suggesting that activation of the HGF/MET pathway might contribute to the recruitment of immunosuppressor neutrophils in the tumor. Our aim was to evaluate the association between HGF serum levels (sHGF) and NC in SCLC and their impact on outcome.
Methods
Serum samples from SCLC patients were obtained before starting first-line treatment. We used the Quantikine Human HGF Immunoassay to quantify sHGF. All samples were run in duplicates. NC and NLR were obtained from blood test reports before treatment initiation. Statistical analysis was carried out using SPSS 22.0 and Prism 8.1.0. Correlation of variables was assessed by the Spearman’s correlation coefficient. Multivariate analysis was performed with the Cox regression method.
Results
Samples from 105 patients diagnosed with SCLC at our institution were included. 79.1% of the cases were male, 73.3% with extensive stage, and 31.4% had an ECOG score of ≥ 2. Median sHGF, NC and NLR were 1875.38pg/ml, 6440/µl and 5.1 respectively. Patients with baseline NLR > 4 or NC above median had worse median overall survival (mOS), with 7.9 vs 15.3 months (m) (p < 0.001) and 7.2 vs 15.3m (p < 0.001) respectively. sHGF above median values was also correlated with worse mOS (7.6 vs 12.8 m; p = 0.005). Baseline sHGF levels were positively correlated with NC (r = 0.34, p < 0.001). In the multivariate analysis for OS, sHGF and NC remained independently associated with poor outcome (HR 1.094; p = 0.001 and HR 1.18; p = 0.003 respectively).
Conclusions
Baseline HGF levels correlate with NC in SCLC, reinforcing the hypothesis of a plausible interplay between HGF/MET axis and the immune system. The role of these parameters as predictive biomarkers of response to immunotherapy in SCLC warrants further investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
E. Arriola: Speaker Bureau / Expert testimony: BMS; Speaker Bureau / Expert testimony: Roche; Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Pfizer; Speaker Bureau / Expert testimony: Lilly; Speaker Bureau / Expert testimony: AstraZeneca; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): PGDx; Travel / Accommodation / Expenses: BMS; Travel / Accommodation / Expenses: MSD; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Lilly. All authors have declared no conflicts of interest.
Resources from the same session
5037 - CXCR4, CCR2 and CCR5 expression in subsets of tumor cells with stem and/or EMT features
Presenter: Olga Savelieva
Session: Poster Display session 1
Resources:
Abstract
5729 - Expression of mutant p53 affects cancer cell sensitivity to topotecan
Presenter: Rimma Mingaleeva
Session: Poster Display session 1
Resources:
Abstract
5725 - Breast cancer organoids a new tool for the prediction of drugs penetration and patient’outcome
Presenter: Giuseppina Roscigno
Session: Poster Display session 1
Resources:
Abstract
5680 - Aptamer-mediated exosomes detection for early breast cancer identification.
Presenter: Cristina Quintavalle
Session: Poster Display session 1
Resources:
Abstract
2460 - MicroRNA-181c promotes tamoxifen resistance in breast cancer cells via upregulation Akt/mTOR axis
Presenter: Alexander Scherbakov
Session: Poster Display session 1
Resources:
Abstract
3751 - Spatio-temporal separation of tumor infiltrating CD8+ T-cells and HER2/neu+ tumor cells in tumor-immune milieu of infiltrating ductal carcinoma of the breast
Presenter: Sandhya Sreedharan
Session: Poster Display session 1
Resources:
Abstract
4664 - Large genomic rearrangements in BRCA1 and BRCA2 genes in the Portuguese population.
Presenter: Joao Pinto
Session: Poster Display session 1
Resources:
Abstract
4611 - Non-BRCA1/2 hereditary breast and ovarian cancer: findings from a multidisciplinary program
Presenter: Ana Monteiro
Session: Poster Display session 1
Resources:
Abstract
5340 - Quantitative imaging and characterization of collagen patterns in high grade serous ovarian carcinoma (HGSOC)
Presenter: Ruby Huang
Session: Poster Display session 1
Resources:
Abstract
4209 - Semiquantitative assessment of vimentin expression in prostate cancer (PC)
Presenter: Marina Puchinskaya
Session: Poster Display session 1
Resources:
Abstract